Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis.

PubWeight™: 1.35‹?› | Rank: Top 10%

🔗 View Article (PMID 10555827)

Published in Curr Opin Neurol on August 01, 1999

Authors

O Stüve1, S S Zamvil

Author Affiliations

1: Department of Neurology, University of Washington, Seattle, USA.

Articles by these authors

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 6.88

Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell (1988) 5.73

T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature (1987) 3.96

Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol (1990) 1.83

Involvement of distinct murine T-cell receptors in the autoimmune encephalitogenic response to nested epitopes of myelin basic protein. Proc Natl Acad Sci U S A (1988) 1.51

Characterization of a major encephalitogenic T cell epitope in SJL/J mice with synthetic oligopeptides of myelin basic protein. J Neuroimmunol (1988) 1.50

Encephalitogenic T cell clones specific for myelin basic protein. An unusual bias in antigen recognition. J Exp Med (1985) 1.46

Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain (2008) 1.37

Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sci U S A (1989) 1.36

Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity. J Clin Invest (2001) 1.36

Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J Immunol (1998) 1.05

Response to the RIF-1 tumor in vitro and in C3H/Km mice to X-radiation (cell survival, regrowth delay, and tumor control), chemotherapeutic agents, and activated macrophages. J Natl Cancer Inst (1980) 1.03

Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. Eur J Immunol (1995) 1.02

T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice. J Exp Med (1994) 0.98

T cell specificity for class II (I-A) and the encephalitogenic N-terminal epitope of the autoantigen myelin basic protein. J Immunol (1987) 0.95

Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. Glia (2001) 0.93

Polymorphic residues on the I-A beta chain modulate the stimulation of T cell clones specific for the N-terminal peptide of the autoantigen myelin basic protein. J Immunol (1989) 0.89

Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology (2012) 0.87

Single nucleotide polymorphisms in MHC2TA, the gene encoding the MHC class II transactivator (CIITA). Genes Immun (2002) 0.85

Comparison of antigen specificity, class II major histocompatibility complex restriction, and in vivo behavior of myelin basic protein-specific T cell lines and clones derived from (BALB/c x SJL/J) mice. J Immunol (1987) 0.84

MRI lesion volume heterogeneity in primary progressive MS in relation with axonal damage and brain atrophy. J Neurol Neurosurg Psychiatry (2003) 0.83

Therapy of autoimmune diseases with antibody to immune response gene products or to T-cell surface markers. Ann N Y Acad Sci (1986) 0.82

Differential expression of B7 co-stimulatory molecules by astrocytes correlates with T cell activation and cytokine production. Int Immunol (1999) 0.82

Statins and demyelination. Curr Top Microbiol Immunol (2008) 0.81

Highlights from the Fifth International Congress of the International Society of Neuroimmunology. J Neuroimmunol (1999) 0.81

TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation. J Leukoc Biol (2010) 0.80

Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis. J Neuroimmunol (2007) 0.80

Spotlight on statins. Int MS J (2007) 0.80

Specific immunotherapy: one size does not fit all. Nat Med (2000) 0.79

Localization of an encephalitogenic epitope for the SJL mouse in the N-terminal region of myelin basic protein. J Neuroimmunol (1990) 0.79

[Statins for treatment of CNS diseases. Status report from research and clinical practice]. Nervenarzt (2005) 0.76

Effect of oral beta interferon on subsequent immune responsiveness. Ann N Y Acad Sci (1996) 0.76

Autoimmune demyelinating disease. West J Med (1989) 0.75

The potential therapeutic role of statins in central nervous system autoimmune disorders. Cell Mol Life Sci (2003) 0.75

Prior exposure to superantigen can inhibit or exacerbate autoimmune encephalomyelitis: T-cell repertoire engaged by the autoantigen determines clinical outcome. J Neuroimmunol (1996) 0.75